⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1090210 | 1.00 | — | — | |
| SCHEMBL15658 | 1.00 | — | — | |
| SCHEMBL17766840 | 1.00 | TSHR (0.47) | — | |
| Methyl Alcohol SCHEMBL19457756 | 0.96 | — | — | |
| Isobutanol SCHEMBL144682 | 0.89 | TSHR (0.60) | — | |
| Alcohol SCHEMBL3796705 | 0.89 | TSHR (0.47) | — | |
| Butanol SCHEMBL1682662 | 0.89 | TSHR (0.67) | — | |
| SCHEMBL21541629 | 0.87 | TSHR (0.37) | — | |
| Bicarbonate SCHEMBL2768596 | 0.87 | RNPEP (0.48) | — | |
| Acetonitrile SCHEMBL11376983 | 0.84 | TSHR (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 162 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11424006-B2 | Targeted drugs associated with trimethylamine and/or trimeihylamine-n-oxide | PSOMAGEN, INC. (US) | 2022-08-23 | — | — | US | claimed |
| US-20210128498-A1 | TARGETED DRUGS ASSOCIATED WITH TRIMETHYLAMINE AND/OR TRIMETHYLAMINE-N-OXIDE | MACROGEN INC. (KR) | 2021-05-06 | — | — | US | claimed |
| EP-3668494-A1 | TARGETED DRUGS ASSOCIATED WITH TRIMETHYLAMINE AND/OR TRIMETHYLAMINE-N-OXIDE | Psomagen, Inc. (US) | 2020-06-24 | — | — | EP | claimed |
| CN-111163761-A | Targeted drugs related to trimethylamine and/or trimethylamine-N-oxide | 普梭梅根公司 | 2020-05-15 | — | — | CN | claimed |
| WO-2019036507-A1 | TARGETED DRUGS ASSOCIATED WITH TRIMETHYLAMINE AND/OR TRIMETHYLAMINE-N-OXIDE | uBiome, Inc. (US) | 2019-02-21 | — | — | WO | claimed |
| US-20190050525-A1 | RIESKE-TYPE OXYGENASE/REDUCTASE TARGETED DRUGS FOR DIAGNOSTIC AND TREATMENT OF DISEASES | PSOMAGEN, INC. | 2019-02-14 | — | — | US | claimed |
| US-12486248-B2 | 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of DHODH | BAYER AKTIENGESELLSCHAFT (DE) | 2025-12-02 | — | — | US | disclosed |
| WO-2025217099-A1 | INHIBITORS FOR HYDROGEN EMBRITTLEMENT AND METHODS | CHEVRON PHILLIPS CHEMICAL COMPANY LP (US) | 2025-10-16 | — | — | WO | disclosed |
| WO-2025217091-A1 | ODORANTS FOR FLUIDS, ODORIZED FLUIDS, METHODS, AND SYSTEMS | CHEVRON PHILLIPS CHEMICAL COMPANY LP (US) | 2025-10-16 | — | — | WO | disclosed |
| WO-2025096734-A1 | MICROCAPSULES | FMC CORPORATION (US) | 2025-05-08 | — | — | WO | disclosed |
| CN-119776301-A | Alcohol dehydrogenase, recombinant genetically engineered bacterium and application thereof in asymmetric reduction of potential chiral carbonyl compounds | 杭州文德阶生物科技有限公司 | 2025-04-08 | — | — | CN | disclosed |
| CN-115557907-B | 2,4, 5-Trisubstituted 1,2, 4-triazolones as DHODH inhibitors | 拜耳股份有限公司 | 2024-12-06 | — | — | CN | disclosed |
| US-20240216377-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE CORPORATION | 2024-07-04 | — | — | US | disclosed |
| US-7265113-B2 | Inhibitors of kinases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-09-04 | — | — | US | disclosed |
| US-20070203183-A1 | Diaryl piperidines as CB1 modulators | SCHERING CORPORATION | 2007-08-30 | — | — | US | disclosed |
| US-7253187-B2 | Heterocyclic inhibitors of ERK2 and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-08-07 | — | — | US | disclosed |
| US-7253187-B2 | Heterocyclic inhibitors of ERK2 and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-08-07 | — | — | US | disclosed |
| US-20070112038-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. | 2007-05-17 | — | — | US | disclosed |
| EP-0398288-B1 | Process for preparing optically active 2-arylalkanoic acids, in particular 2-arylpropionic acids | PUETTER MEDICE CHEM PHARM (DE) | 1995-10-18 | — | — | EP | disclosed |
| EP-0398288-A2 | Process for preparing optically active 2-arylalkanoic acids, in particular 2-arylpropionic acids | MEDICEChem.-Pharm. Fabrik Pütter GmbH & Co. KG (DE) | 1990-11-22 | — | — | EP | disclosed |